Fate’s investor syndicate brings a wealth of experience in supporting the emergence of top biopharmaceutical companies.
Each of Fate’s four venture capital investors have nurtured companies in discovering, developing and commercializing innovative biopharmaceutical products and disruptive technologies that have shaped the health care ecosystem. Fate’s three corporate investors have sought investments in companies forging into new areas of biology and into the development of medicines addressing critical unmet needs.
 |
 |
ARCH VENTURE PARTNERSARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in information technology, life sciences, and physical sciences. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages six funds totaling over $1.4 billion and has invested in the earliest venture capital rounds for more than 110 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. The partnership is led by seven managing directors and a team of venture partners, principals, and technology specialists. |
ASTELLAS VENTURE MANAGEMENTInvestment in emerging biotechnology companies, Astellas Venture Management LLC (AVM) is the corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company originated in Japan. The venture capital activity of AVM can trace back to Astellas Venture Capital LLC (originally founded as Yamanouchi VentureCapital LLC in 2000) and Fujisawa Investments for Entrepreneurship LP established in 1999. AVM is currently managing four funds. |
 |
 |
GENZYME VENTURESGenzyme Ventures is a corporate venture capital fund dedicated to helping Genzyme Corporation achieve its strategic goals. Founded in 2001, the $100 million fund has a current portfolio of direct corporate investments and has taken LP positions in funds managed by life-science focused VC firms. Through its direct investments in private early-stage companies, the fund aims to forge relationships which may lead to larger collaborations in the future. Genzyme Ventures is able to leverage the entire Genzyme organization, including its global experience and expertise in R&D, reimbursement, and commercialization, to provide portfolio companies with invaluable advice and assistance. Its Limited Partnership investments provide insight into the broader healthcare innovation landscape. |
OVP VENTURE PARTNERSFor over 24 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVP’s strategy of focusing on early-stage investments in defined spaces has yielded proven results; the firm’s record of 52 liquidity events – including 22 IPOs – leads the region. The OVP team has a passion for working with ground-breaking entrepreneurs and high-caliber investors, and is known for its track record and personal integrity. OVP has over $750 million in capital under management and is currently investing its seventh fund.OVP has offices in Seattle and Portland and concentrates on opportunities at the intersection of technology’s next big waves and foundational strengths native to the region. The firm’s recent activity has included deals in communications, software, security, semiconductors, digital biology, and nanotechnology. |
 |
 |
POLARIS VENTURE PARTNERSPolaris Venture Partners is a partnership of experienced venture capital investors and technology executives. The firm’s mission is to identify and invest in seed, first round, and early stage information technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies. In addition, Polaris is committed to providing growth equity and shareholder liquidity to established companies in the technology, healthcare, manufacturing, media, communications, and business services sectors. As a national venture capital firm with offices in the high-tech centers of Boston and Seattle, Polaris is able to invest in businesses throughout the United States and around the world. The firm has over $3 billion under management and current investments in more than 90 companies. |
TAKEDA VENTURESTakeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. TVI now assumes the role of Takeda’s former venture investment group, Takeda Research Investment, Inc., and remains a wholly owned subsidiary of Takeda America Holdings, Inc.. The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. Our aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company. |
 |
|
VENROCKVenrock is a premier venture capital firm with offices in Menlo Park, New York, Cambridge, MA, and Israel, with a primary focus on technology, healthcare, and energy. Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $1.9 billion in 405 companies resulting in 124 IPOs and 114 M&A exits over the past 38 years, Venrock’s investment returns place it among the top tier venture capital firms that have achieved consistently superior performance. |